Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Survodutide | Mazdutide |
|---|---|---|
| Class | Dual GLP-1 / glucagon receptor agonist | Dual GLP-1 / glucagon receptor agonist |
| Research category | obesity and steatohepatitis (MASH) | obesity and type 2 diabetes |
| Evidence level | Moderate | Moderate |
| Overall status | Not approved — phase 3 clinical research | Approved in China; investigational elsewhere |
| FDA | Not approved | Not approved |
| EMA | Not approved | Not approved |
| WADA | Check current list | Check current list |
| Mechanism studied | Survodutide → GLP-1R + GCGR → Hepatic lipid oxidation → Liver & weight endpoints | Mazdutide → GLP-1R + GCGR → Satiety & energy expenditure → Weight & glucose endpoints |
| Molecular weight | 4,232 g/mol | 4,476 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Survodutide is classed as dual glp-1 / glucagon receptor agonist, while Mazdutide is dual glp-1 / glucagon receptor agonist. Evidence is rated moderate for Survodutide and moderate for Mazdutide.
For a full write-up, read GLP-1/Glucagon Co-agonists: Survodutide and Mazdutide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.